Back to results
US 12,109,231 B2Granted
Treatment of neurodegenerative disease with sodium chlorite
AssigneesNeuvivo, Inc., The Regents of the University of California
InventorsVernon A. Norviel, Michael S. McGrath
Life of this patent
Estimating the term…
Abstract
The present invention provides a method of treating frontotemporal dementia, or a childhood genetic neurodegenerative disease such as Ataxia Telangiectasia (A-T), or neurodegenerative diseases such as Parkinson's disease or neuropsychiatric diseases comprising administering to a subject in need thereof an effective amount of chlorite composition, such as sodium chlorite. The present invention thereby provides a method of modulating the immune system in a subject in need thereof. Described herein are methods of administration and treatment.
Claims20
A method comprising:
- a) administering to a subject who has Amyotrophic Lateral Sclerosis (ALS) a regimen of sodium chlorite;
- and
- b) monitoring a plasma level of C-reactive protein in the subject during the regimen of sodium chlorite and determining based on the monitoring that the plasma level of C-reactive protein in the subject is at least 1125 ng/mL,
- wherein the subject is human;
- wherein the subject exhibits a symptom of Amyotrophic Lateral Sclerosis (ALS);
- wherein the sodium chlorite is administered in an amount ranging from 0.1 to 10 mg/kg by body weight of the subject;
- wherein the administering occurs at least once per month for a period of at least a year;
- and
- wherein the administering occurs over a period ranging from about 0.5 to about 4 hours.
6 more elements
A method comprising:
- a) administering to a subject who has Amyotrophic Lateral Sclerosis (ALS) a regimen of sodium chlorite;
- and
- b) monitoring a plasma level of C-reactive protein in the subject during the regimen of sodium chlorite and determining based on the monitoring that the plasma level of C-reactive protein in the subject is at least 1125 ng/mL,
- wherein the subject is human;
- wherein the subject exhibits a behavioral symptom of Amyotrophic Lateral Sclerosis (ALS);
- wherein the subject exhibits a physical symptom of Amyotrophic Lateral Sclerosis (ALS);
- wherein the sodium chlorite is administered in an amount ranging from 1 to 2 mg/kg by body weight of the subject;
- wherein the administering occurs at least once per month for a period of at least a year;
- wherein the administering occurs over a period ranging from about 0.5 to about 4 hours;
- wherein the administering is parenteral;
- and
- wherein the administering of the sodium chlorite is by administration of a formulation,
- wherein the formulation comprises:
- a) the sodium chlorite;
- b) phosphate buffer;
- c) chloride ions in an amount of less than about 1% of chlorite ions in the formulation;
- and
- d) chlorate ions in an amount of less than about 1.5% of chlorite ions in the formulation,
- wherein the formulation has a pH of about 7 to about 11.
16 more elements
A method comprising:
- a) administering to a subject who has Amyotrophic Lateral Sclerosis (ALS) a regimen of sodium chlorite;
- and
- b) monitoring a plasma level of C-reactive protein in the subject during the regimen of sodium chlorite and determining based on the monitoring that the plasma level of C-reactive protein in the subject is at least 1125 ng/mL,
- wherein the subject is human;
- wherein the subject exhibits a speech disorder;
- wherein the subject exhibits poor coordination;
- wherein the subject exhibits progressive muscle weakness;
- wherein the subject exhibits progressive muscle wasting;
- wherein the subject exhibits respiratory failure;
- wherein the sodium chlorite is administered in an amount ranging from 1 to 2 mg/kg by body weight of the subject;
- wherein the administering occurs at least once per month for a period of at least a year;
- wherein the administering occurs over a period ranging from about 0.5 to about 4 hours;
- wherein the administering is intravenous;
- and
- wherein the administering of the sodium chlorite is by administration of a formulation,
- wherein the formulation comprises:
- a) the sodium chlorite;
- b) phosphate buffer;
- c) chloride ions in an amount from about 0.1% to about 0.5% of chlorite ions in the formulation;
- and
- d) chlorate ions in an amount from about 0.1% to about 0.5% of chlorite ions in the formulation,
- wherein the formulation has a pH of about 7 to about 9.5.
19 more elements
Dependencies are inferred from the claim text.